ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ZBIO vs PGEN // NET PROFIT MARGIN

Zenas BioPharma Inc. (NASDAQ) VS. Precigen Inc. (NASDAQ) • 15-METRIC TALLY: ZBIO 2 — PGEN 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZBIO VS. PGEN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ZBIO PGEN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -9.19% -3.78% -5.41 PGEN /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin ACTIVE -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 100.00% 146.70% -46.70 PGEN /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.79 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 ZBIO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.9 32.6 +15.30 ZBIO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.80B $1.84B -$40.1M PGEN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ZBIO REV PGEN REV ZBIO GROSS % PGEN GROSS % ZBIO FCF PGEN FCF
FY 2025 $10.0M $9.7M — — -$172.4M -$89.8M
FY 2024 $5.0M $3.9M — — -$119.8M -$76.8M
FY 2023 $50.0M $6.2M — — -$30.5M -$66.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZBIO // BETA —
PGEN // BETA —